Literature DB >> 12118570

Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.

M L Woods1, C J Koch, E M Lord.   

Abstract

PURPOSE: The purpose of this work was to evaluate EF5, a 2-nitroimidazole compound, and anti-EF5 antibodies as a method to quantify radiobiologically hypoxic cells. METHODS AND MATERIALS: Multicellular spheroids of EMT6 mammary sarcoma cells were used as a model to identify hypoxic cells that were resistant to radiation damage. This was accomplished by incubating the spheroids with the 2-nitroimidazole (EF5), which forms hypoxia-dependent adducts with cellular macromolecules that are detected by fluorescent monoclonal antibodies.
RESULTS: Cells from spheroids grown for 2 days in sealed flasks had an increased surviving fraction following radiation as compared to fully reoxygenated spheroids, indicating the presence of radiobiological hypoxia. Treatment of the spheroids with EF5 and subsequent immunohistochemical staining of cryosections with an anti-EF5 fluorochrome conjugated monoclonal antibody allowed for the identification of EF5-adduct containing cells. Spheroids grown under hypoxic conditions in the presence of EF5 showed limited staining of the peripheral cell layers, intense staining of the interior, and an absence of staining within the necrotic center. In contrast, there was minimal staining in reoxygenated spheroids and no staining in control spheroids incubated in the absence of EF5. Flow cytometric analysis of single cells dissociated from spheroids allowed for the calculation of the percentage of stained cells, as well as the intensity of staining. A comparison of the intensity of staining of EF5 treated hypoxic spheroids with the intensity of staining of single cells incubated with EF5 under controlled oxygen concentrations was used to estimate the oxygen concentration range within spheroids. Selective dissociation of spheroids provided a direct demonstration that the cells containing the highest level of EF5 binding were also the cells with increased radiation resistance.
CONCLUSION: This technique provides an excellent means of detecting and quantifying hypoxia, which should be directly applicable in tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 12118570     DOI: 10.1016/0360-3016(95)02006-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.

Authors:  J Matthews; H Adomat; N Farrell; P King; C Koch; E Lord; B Palcic; N Poulin; J Sangulin; K Skov
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

3.  Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.

Authors:  I M Pires; M M Olcina; S Anbalagan; J R Pollard; P M Reaper; P A Charlton; W G McKenna; E M Hammond
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

4.  Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia.

Authors:  S M Evans; K M Laughlin; C R Pugh; C M Sehgal; H M Saunders
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  A method for estimating the oxygen consumption rate in multicellular tumour spheroids.

Authors:  David Robert Grimes; Catherine Kelly; Katarzyna Bloch; Mike Partridge
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

6.  Germinal centre hypoxia and regulation of antibody qualities by a hypoxia response system.

Authors:  Sung Hoon Cho; Ariel L Raybuck; Kristy Stengel; Mei Wei; Thomas C Beck; Emmanuel Volanakis; James W Thomas; Scott Hiebert; Volker H Haase; Mark R Boothby
Journal:  Nature       Date:  2016-08-08       Impact factor: 49.962

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.